Breast and ovarian cancers belong to the most common malignancies diagnosed in women. The major inherited susceptibilities to breast and ovarian cancers are germline mutations in either *BRCA1* or *BRCA2* which however, explain only small number of breast and ovarian cancer cases. Data suggest that majority breast and ovarian cancers are caused by low or moderate penetrance gene mutations. Identification of such mutations provides cancer risk assessment and will help in prophylactic, early diagnosis and treatment.

In 2005 three international multidisciplinary consortia have been initiated: **Breast Cancer Association Consortium** (BCAC), **Consortium of Investigators of Modifiers of BRCA1/2** (CIMBA) and **Ovarian Cancer Association Consortium** (OCAC) which are forums of investigators from centers over the world, including International Hereditary Cancer Center in Szczecin. The aim of these consortia's is to combine data from many studies, to provide a reliable assessment of the breast and ovarian cancer risks associated with different genetic and environmental factors, and to identify potential modifiers of cancer risk in carriers of BRCA1 and BRCA2 mutation.

**BCAC** includes 54 centers (table [1](#T1){ref-type="table"}) over the world and focuses on identification of genes associated with breast cancer risk.

###### 

Centers collaborating in BCAC

  Name                                                                        Acronym           Country
  --------------------------------------------------------------------------- ----------------- -------------
  Australian Breast Cancer Family Study                                       ABCFS             Australia
  Amsterdam Breast Cancer Study                                               ABCS              Netherlands
  Australian Breast Cancer Tissue Bank                                        ABCTB             Australia
  Asia Cancer Program                                                         ACP               Thailand
  Bavarian Breast Cancer Cases and Controls                                   BBCC              Germany
  British Breast Cancer Study                                                 BBCS              UK
  Breast Cancer In Galway Genetic Study                                       BIGGS             Ireland
  Breast Cancer Study of the University Clinic Heidelberg                     BSUCH             Germany
  CECILE Breast Cancer Study                                                  CECILE            France
  Copenhagen General Population Study                                         CGPS              Denmark
  Spanish National Cancer Centre Breast Cancer Study                          CNIO-BCS          Spain
  California Teachers Study                                                   CTS               USA
  ESTHER Breast Cancer Study                                                  ESTHER            Germany
  ICR Familial Breast Cancer Study                                            FBCS              UK
  German Consortium for Hereditary Breast & Ovarian Cancer                    GC-HBOC (GFBCS)   Germany
  Gene Environment Interaction and Breast Cancer in Germany                   GENICA            Germany
  Genetic Epidemiology Study of Breast Cancer by Age 50                       GESBC             Germany
  Hannover Breast Cancer Study                                                HABCS (HBCS)      Germany
  Helsinki Breast Cancer Study                                                HEBCS             Finland
  Hannover-Minsk Breast Cancer Study                                          HMBCS             Belarus
  Hannover-Ufa Breast Cancer Study                                            HUBCS             Russia
  Karolinska Breast Cancer Study                                              KARBAC            Sweden
  Kuopio Breast Cancer Project                                                KBCP              Finland
  kConFab/AOCS                                                                kConFab/AOCS      Australia
  Leuven Multidisciplinary Breast Centre                                      LMBC              Belgium
  Mammary Carcinoma Risk Factor Investigation                                 MARIE             Germany
  Milan Breast Cancer Study Group                                             MBCSG             Italy
  Mayo Clinic Breast Cancer Study                                             MCBCS             USA
  Melbourne Collaborative Cohort Study                                        MCCS              Australia
  Multi-ethnic Cohort                                                         MEC               USA
  Memorial Sloan-Kettering Cancer Center                                      MSKCC             USA
  Mexican Case Control Study of Breast Cancer                                 MXCCS             Mexico
  Malaysian Breast Cancer Genetic Study                                       MYBRCA            Malaysia
  Norwegian Breast Cancer Study                                               NBCS              Norway
  Northern California Breast Cancer Family Registry                           NC-BCFR           USA
  Nurses Health Study                                                         NHS               USA
  Nigerian Breast Cancer Study                                                NGBCS             Nigeria
  Oulu Breast Cancer Study                                                    OBCS              Finland
  Ontario Familial Breast Cancer Registry                                     OFBCR             Canada
  Leiden University Medical Centre Breast Cancer Study                        ORIGO (LUMCBCS)   Netherlands
  NCI Polish Breast Cancer Study                                              PBCS              Poland
  Prospective Study of Outcomes in Sporadic Versus Hereditary Breast Cancer   POSH              UK
  Rotterdam Breast Cancer Study                                               RBCS              Netherlands
  Singapore and Sweden Breast Cancer Study                                    SASBAC            Sweden
  Sheffield Breast Cancer Study                                               SBCS              UK
  Study of Epidemiology and Risk factors in Cancer Heredity                   SEARCH            UK
  Seoul Breast Cancer Study                                                   SEBCS (SBCP)      Korea
  **IHCC-Szczecin Breast Cancer Study**                                       **SZBCS**         **Poland**
  IARC-Thai Breast Cancer Study                                               TBCS              Thailand
  Taiwanese Breast Cancer Study                                               TWBCS             Taiwan
  UCI Breast Cancer Study                                                     UCIBCS            USA
  UK Breakthrough Generations Study                                           UKBGS             UK
  US Three State Study                                                        US3SS             USA
  US Radiologic Technologists Study                                           USRTS             USA

Currently, BCAC database includs demographic, clinical and epidemiological data from 73,000 breast cancer patients and 80,000 unaffected women. Up to now, 125 genetic alterations (SNPs) localized in different genes have been examined. These SNPs have been selected based on its positive association with breast cancer risk detected in preliminary analyses or Genome-Wide Association Study (GWAS). Results have been presented in 12 manuscripts published in high impact journals, e.g. J Natl Cancer Inst, Nature and Nat Genet (<http://www.srl.cam.ac.uk/consortia/bcac/pubs/pubs.html>).

Ten SNPs have been found to be associated with breast cancer risk overall or by clinical and pathological characteristics (table [2](#T2){ref-type="table"}).

###### 

BCAC SNPs associated with breast cancer risk overall or by clinical and pathological characteristics

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene / SNP          Breast cancer risk                                                                      BCAC manuscript
  ------------------- --------------------------------------------------------------------------------------- -------------------------------------------
  CASP8 D302H         CG v. GG: OR 0.89, 95% CI 0.85-0.94\                                                    *Cox et al.*, *Nat Genet 2007*
                      CC v. GT: OR 0.74, 95% CI 0.62-0.87                                                     

                                                                                                              

  FGFR2, rs2981582\   OR~hom~ 1.63, 95% CI 1.53-1.72, p=4.1 × 10^-76^\                                        *Easton et al.*, *Nat Genet 2007*
  TNRC9, rs3803662\   OR~hom~ 1.39, 95% CI 1.25-1.45, p=1.4 × 10^-36^\                                        
  MAP3K1, rs889312\   OR~hom~ 1.27, 95% CI 1.19-1.36, p=4.1 × 10^-20^\                                        
  LSP, rs3817198\     OR~hom~ 1.17, 95% CI 1.08-1.25, p=4.1 × 10^-9^\                                         
  8q24, rs13281615    OR~hom~ 1.18, 95% CI 1.10-1.25, p=4.1 × 10^-12^                                         

                                                                                                              

  FGFR2, 2981582\     ER positive:p=10^-13^\                                                                  *Garcia-Closas et al.*, *PLoS Genet 2008*
  \                   PGR positive: p=10^-5^\                                                                 
  \                   low grade: p=10^-8^\                                                                    
  \                   metastases: p=0.013\                                                                    
  \                   \                                                                                       
  8q24, 13281615\     ER positive: p=0.001\                                                                   
  \                   PGR positive: p=0.011\                                                                  
  \                   low grade: p=10^-4^\                                                                    
  \                   \                                                                                       
  TNRC9, rs3803662    ER negative: OR 1.14, 95% CI 1.09-1.21                                                  

                                                                                                              

  AKAP9 M463I         TT v. GG:\                                                                              *Frank et al.*, *JNCI 2008*
                      OR 1.17, 95% CI 1.08-1.27, p=0.0003\                                                    
                      familial cases: OR 1.27, 95% CI 1.12-1.45, p=0.0003\                                    
                      \                                                                                       
                      TT v. GT:\                                                                              
                      OR 1.10, 95% CI 1.04-1.17, p=0.001\                                                     
                      familial cases: OR 1.16, 95% CI 1.06-1.27, p=0.001                                      

                                                                                                              

  3p24, rs4973768\    OR~per-allele~ 1.11, 95% CI 1.08-1.13, p=4.1 × 10^-23^\                                 *Ahmed et al.*, *Nat Genet 2009*
  \                   \                                                                                       
  17q23, rs6504950    OR~per-allele~ 0.95, 95% CI 0.92-0.97, p=1.4 × 10^-8^                                   

                                                                                                              

  2q35, rs13387042    OR ~per-allele~ 1.12, 95% CI 1.09 -1.15; p~trend~ 1.0 × 10^-19^ (European Caucasian)\   *Milane et al.*, *JNCI 2009*
                      ER positive: OR 1.14, 95% CI 1.10-1.17; p=10^-15^\                                      
                      ER negative: OR 1.10, 95% CI 1.04-1.15; p=0.0003\                                       
                      PGR positive: OR 1.15, 95% CI 1.11-1.19; p=5 × 10^-14^\                                 
                      PGR negative: OR 1.10, 95% CI 1.06-1.15; p=0.00002                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------

CIMBA database contains demographic, clinical and epidemiological data from 15,700 BRCA1 and 8,600 BRCA2, mutation carriers including 12,700 breast cancer patients, 2,500 ovarian cancer patients and 9,100 unaffected patients from 42 centers over the world (table [3](#T3){ref-type="table"}).

###### 

Centers collaborating in CIMBA

  Study                                                                                    Acronym       Country
  ---------------------------------------------------------------------------------------- ------------- -----------------------
  Breast Cancer Family Registry                                                            BCFR          USA/Australia
  Baltic Familial Breast Ovarian Cancer Consortium                                         BFBOCC        Latvia/Lithuania
  BRCA-gene mutations and breast cancer in South African women                             BMBSA         South Africa
  Rigshospitalet                                                                           CBCS          Denmark
  Spanish National Cancer Centre                                                           CNIO          Spain
  CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella                              CONSIT TEAM   Italy
  German Cancer Research Center                                                            DKFZ          Germany
  Genen Omgeving studie van de werkgroep Hereditiair Borstkanker Onderzoek Nederland       DNA HEBON     Netherlands
  Epidemiological Study of Familial Breast Cancer                                          EMBRACE       UK
  Fox Chase Cancer Center                                                                  FCCC          USA
  German Familial Breast Group                                                             GC-HBOC       Germany
  Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers                            GEMO          France/Greece/USA
  Georgetown University                                                                    GEORGETOWN    USA
  Gynecologic Oncology Group                                                               GOG           USA
  Hospital Clinico San Carlos                                                              HCSC          Spain
  Helsinki Breast Cancer Study                                                             HEBCS         Finland
  Study of Genetic Mutations in Breast and Ovarian Cancer patients in Hong Kong and Asia   HRBCP         Hong Kong
  Molecular Genetic Studies of Breast- and Ovarian Cancer in Hungary                       HUNBOCS       Hungary
  Institut Català d\'Oncologia                                                             ICO           Spain
  **International Hereditary Cancer Centre**                                               **IHCC**      **Poland**
  Iceland Landspitali - University Hospital                                                ILUH          Iceland
  INterdisciplinary HEalth Research Internal Team BReast CAncer susceptibility             INHERIT       Canada
  Istituto Oncologico Veneto                                                               IOVHBOCS      Italy
  Kathleen Cuningham Consortium for Research into Familial Breast Cancer                   KCONFAB       Australia/New Zealand
  Korean Hereditary Breast Cancer Study                                                    KOHBRA        Korea
  Modifiers and Genetics in Cancer                                                         MAGIC         USA
  Mayo Clinic                                                                              MAYO          USA
  Modifier Study of Quantitative Effects on Disease                                        MOD SQUAD     USA
  Memorial Sloane Kettering Cancer Center                                                  MSKCC         USA
  General Hospital Vienna                                                                  MUV           Austria
  National Cancer Institute                                                                NCI           USA
  National Israeli Cancer Control Center                                                   NICCC         Israel
  N.N. Petrov Institute of Oncology                                                        NNPIO         Russia
  Ontario Cancer Genetics Network                                                          OCGN          Canada
  The Ohio State University Comprehensive Cancer Center                                    OSU CCG       USA
  Odense University Hospital                                                               OUH           Denmark
  Università di Pisa                                                                       PBCS          Italy
  South East Asian Breast Cancer Association Study                                         SEABASS       Malaysia/Singapore
  Sheba Medical Centre                                                                     SMC           Israel
  Swedish Breast Cancer Study                                                              SWE-BRCA      Sweden
  University of California Irvine                                                          UCI           USA
  University of California San Francisco                                                   UCSF          USA
  UK and Gilda Radner Familial Ovarian Cancer Registries                                   UKGRFOCR      UK/USA
  University of Pennsylvania                                                               UPENN         USA
  Cedars-Sinai Medical Center                                                              WCRI          USA

Results have been presented in 9 manuscripts published in high impact journals, e.g. Am. J Hum Genet, Hum Mol Genet (<http://www.srl.cam.ac.uk/consortia/cimba/pubs/pubs.html>).

Six SNPs have been found to be associated with breast cancer risk (table [4](#T4){ref-type="table"}).

###### 

SNPs associated with breast cancer risk in BRCA1/2 carriers

  -----------------------------------------------------------------------------------------------------------------------
  Gene / SNP          Breast cancer risk                                           CIMBA manuscript
  ------------------- ------------------------------------------------------------ --------------------------------------
  RAD51, rs11683487   BRCA2: HR~hom~ 3.18, 95% CI 1.39-7.27, p=0.0007              *Antoniou et al. AJHG 2007*

                                                                                   

  TNRC9, rs3803662\   BRCA1/2: HR 1.13, 95% CI: 1.06-1.20, p~trend~= 5 × 10^-5^\   *Antoniou et al. AJHG 2008*
  FGFR2, rs2981582\   BRCA2: HR 1.32, 95% CI: 1.20-1.45, p~trend~=1.7 × 10^-8^\    
  MAP3K1, rs889312    BRCA2: HR 1.12, 95% CI: 1.02-1.24, p~trend~=0.02             

                                                                                   

  2q35, rs13387042\   BRCA1: HR 1.14, 95% CI: 1.04-1.25, p=0.0047\                 *Antoniou et al. Hum Mol Genet 2008*
  LSP1, rs3817198\    BRCA2: HR 1.16, 95% CI: 1.07-1.25, p~trend~=2.8 × 10^-4^\    
  2q35, rs13387042    HR 1.18 95% CI: 1.04-1.33, p=0.0079                          
  -----------------------------------------------------------------------------------------------------------------------

**OCAC** includes 24 centers over the world and focuses on identification of genes that may be related to the risk of ovarian cancer (table [5](#T5){ref-type="table"}).

###### 

Centers collaborating in OCAC

  Name                                                                           Acronym    OCAC Acronym   Country
  ------------------------------------------------------------------------------ ---------- -------------- -------------
  Australian Ovarian Cancer Study and Australian Cancer Study (Ovarian Cancer)   AOCS/ACS   AUS            Australia
  Bavarian Ovarian Cancer Cases and Controls                                     BOCC       BAV            Germany
  Belgian Ovarian Cancer Study                                                   BELOCS     BEL            Belgium
  Connecticut Ovary Study                                                        (none)     CON            USA
  Diseases of the Ovary and their Evaluation Study                               DOVE       DOV            USA
  German Ovarian Cancer Study                                                    GOCS       GER            Germany
  Hawaii Ovarian Cancer Study                                                    (none)     HAW            USA
  Hannover-Jena Ovarian Cancer Study                                             HJOCS      HJO            Germany
  Hannover-Minsk Ovarian Cancer Study                                            HMOCS      HMO            Germany
  Helsinki Ovarian Cancer Study                                                  HOCS       HOC            Finland
  Hormones and Ovarian Cancer Prediction                                         HOPE       HOP            USA
  **Polish Ovarian Cancer Study**                                                **POCS**   **JAC**        **Poland**
  Women\'s Cancer Research Institute (Cedars-Sinai Medical Center)               WCRI       LAX            USA
  The Danish Malignant Ovarian Tumour Study                                      MALOVA     MAL            Denmark
  Mayo Clinic Ovarian Cancer Case Control Study                                  (none)     MAY            USA
  Melbourne Collaborative Cohort Study                                           MCCS       MCC            Australia
  Memorial Sloan Kettering Cancer Center Gynecology Tissue Bank                  MSKGTB     MSK            USA
  North Carolina Ovarian Cancer Study                                            NCOCS      NCO            USA
  New England-based Case-Control Study of Ovarian Cancer                         NECC       NEC            USA
  Nurses Health Study                                                            NHS        NHS            USA
  New Jersey Ovarian Cancer Study                                                NJOCS      NJO            USA
  Nijmegen Polygene Study & Nijmegen Biomedical Study                            POLYGENE   NTH            Netherlands
  Prognostic Factors in Epithelial Ovarian Cancer                                EOC        NTX            Netherlands
  Ovarian Cancer in Alberta and British Columbia Study                           OVAL-BC    OVA            Canada
  NCI Ovarian Case-Control Study in Poland                                       NCI-OCS    POL            Poland
  Roswell Park Cancer Institute Cases                                            RPCI       RPX            USA
  UK SEARCH Ovarian Cancer Study                                                 SEARCH     SEA            UK
  Southampton Ovarian Cancer Study                                               (none)     SOC            UK
  Genetic Epidemiology of Ovarian Cancer                                         GEOCS      STA            USA
  Tampa Bay Ovarian Cancer Study                                                 TBOCS      TBO            USA
  Familial Ovarian Tumour Study                                                  FOTS       TOR            Canada
  UC Irvine Ovarian Cancer Study                                                 (none)     UCI            USA
  UK Ovarian Cancer Population Study                                             UKOPS      UKO            UK
  Los Angeles County Case-Control Studies of Ovarian Cancer                      LAC-CCOC   USC            USA

Currently, OCAC database includs demographic, clinical and epidemiological data from 22,000 ovarian cancer patients and 18,000 unaffected women. Several genetic alterations (SNPs) localized in different genes have been examined. Results have been presented in 13 manuscripts published in high impact journals, e.g. Nat Genet, Cancer Res, In J Cancer (<http://www.srl.cam.ac.uk/consortia/ocac/pubs/pubs.html>).

Seven SNPs have been found to be associated with ovarian cancer risk overall or by clinical and pathological characteristics (table [6](#T6){ref-type="table"}).

###### 

SNPs associated with ovarian cancer risk

  ------------------------------------------------------------------------------------------------------------------------
  Gene / SNP           Ovarian cancer risk                                       OCAC manuscript
  -------------------- --------------------------------------------------------- -----------------------------------------
  CDKN2A, rs3731257\   OR 0.91, 95% CI 0.85-0.98, p=0.008\                       *Gayther et al.*, *Cancer Res 2007*
  CDKN1B, rs2066827    OR 0.93, 95% CI 0.87-0.995, p=0.036                       

                                                                                 

  TP53, 23 SNPs:\      OR~per-allele~ 1.30, 95% CI 1.07-1.57\                    *Schildkraut et al.*, *Cancer Res 2009*
  rs2287498\           OR~per-allele~ 1.19, 95% CI 1.01-1.38                     
  rs12951053                                                                     

                                                                                 

  NMI, rs11683487      OR 0.89, 95% CI 0.80-0.99, p=0.032                        *Quaye et al.*, *BJC 2009*

                                                                                 

  CYP3A4, rs2740574    OR~hom~ 2.81, 95% CI 1.20-6.56, p=0.017                   *Pearce et al.*, *BJC 2009*

                                                                                 

  9p22.2, rs3814113    OR 0.82, 95% CI 0.79-0.86, p=5.1×10^-19^\                 *Song et al.*, *Nat Genet 2009*
                       serous tumors: OR 0.77, 95% CI 0.73-0.81, p=4.1×10^-21^   
  ------------------------------------------------------------------------------------------------------------------------
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